Skip to main content
Menu Icon Menu Icon
Close

InfoBytes Blog

Financial Services Law Insights and Observations

DOJ Settles False Claims Act Allegations Against Pharmaceutical Manufacturer

DOJ Whistleblower False Claims Act / FIRREA

Federal Issues

On February 11, the DOJ announced a $7.9 million settlement with a Delaware-based pharmaceutical manufacturer for allegedly violating the False Claims Act by engaging in a kickback scheme with a pharmacy benefits manager corporation. The pharmaceutical manufacturer denies the DOJ’s allegations that it paid $40 million to a pharmacy benefits manager corporation in exchange for “sole and exclusive” recommendation of a certain drug. According to the two whistleblowers, both former employees for the accused pharmaceutical manufacturer, the accused manufacturer paid the pharmacy benefits manager “through price concessions on [other] drugs.” Under the whistleblower provision of the False Claims Act, the two former employees will receive a combined payment of $1,422,000.

Share page with AddThis